Innate Pharma S.A. (IPHA)
| Market Cap | 135.84M -24.2% |
| Revenue (ttm) | 11.21M -22.4% |
| Net Income | -54.22M |
| EPS | -0.58 |
| Shares Out | 93.70M |
| PE Ratio | n/a |
| Forward PE | 20.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,234 |
| Open | 1.470 |
| Previous Close | 1.430 |
| Day's Range | 1.462 - 1.580 |
| 52-Week Range | 1.170 - 2.710 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 6.67 (+350.68%) |
| Earnings Date | Sep 17, 2026 |
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant... [Read more]
Financial Performance
In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for IPHA stock is "Strong Buy." The 12-month stock price target is $6.67, which is an increase of 350.68% from the latest price.
News
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi...
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi...
Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22
The average one-year price target for Innate Pharma S.A. - Depositary Receipt (NASDAQGS:IPHA) (MUN:IDDA) has been revised to $8.22 / share. This is an increase of 27.91% from the prior estimate of $6....
Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript
Lacutamab advances toward accelerated approval as ADC pipeline expands.
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and comp...
Innate Pharma Earnings Call Transcript: Q2 2026
Strategic partnerships and financing have strengthened the balance sheet, enabling advancement of key programs including lacutamab, IPH4502, and monalizumab. Multiple clinical catalysts are expected in H2 2026, with cash runway projected through Q1 2028.
Innate Pharma Earnings release: Q2 2026
Innate Pharma released its Q2 2026 earnings on September 17, 2026, summarizing the period's financial results.
Innate Pharma Earnings release: Q2 2026
Innate Pharma released its Q2 2026 earnings on September 17, 2026, summarizing the period's financial results.
Innate Pharma Quarterly report: Q2 2026
Innate Pharma has published its Q2 2026 quarterly earnings report on September 17, 2026.
Innate Pharma Slides: Q2 2026
Innate Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 17, 2026.
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
IPHA Looks 1328.6% Overvalued on GF Value™
IPHA Looks 1328.6% Overvalued on GF Value™
Innate Pharma SA: Innate Pharma Reports First Half 2026 Business Update and Financial Results
New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing co...
Innate Pharma Reports First Half 2026 Business Update and Financial Results
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2026. The consolid...
Innate Pharma Reports First Half 2026 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results fo...
Innate Pharma SA: Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD 75 million ...
Innate Pharma says previously announced partnership with Sobi now effective
Innate Pharma (IPHA) “announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other ...
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective followi...
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strate...
Innate Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted a strategic focus on three core assets, with key partnerships supporting late-stage development and commercialization. Upcoming data from IPH4502 and PACIFIC-9 are major catalysts, while innovative ADC approaches and regulatory milestones are expected to drive future growth.
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a confer...
Innate Pharma SA: Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today anno...
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing i...
Innate Pharma price target raised to $9 from $8 at BTIG
BTIG analyst Jeet Mukherjee raised the firm’s price target on Innate Pharma (IPHA) to $9 from $8 and keeps a Buy rating on the shares. The firm notes that the…
Innate Pharma SA To Hold Conference Call Transcript
Innate Pharma SA To Hold Conference Call Transcript